Clinical Trial: A Phase 1 Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670858) titled 'A Phase 1 Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)' on June 22.

Brief Summary: The goal of this clinical trial is to determine safety, tolerability, pharmacokinetics, preliminary efficacy, and MTD, of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma (BCC). The main questions it aims to answer are:

* Is FLD-103 safe and well tolerated?

* What is a safe dose of FLD-103 for future studies?

* How much FLD-103 enters the bloodstream and how long does it take to be cleared from the body?

* Does FLD-103 reduce the size of the tumor?

Participants will:

* Receive either a s...